Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARWR | Arrowhead Pharmaceuticals, Inc.

Index	RUT	P/E	-	EPS (ttm)	-1.71	Insider Own	3.40%	Shs Outstand	107.00M	Perf Week	-5.81%
Market Cap	3.08B	Forward P/E	-	EPS next Y	-2.77	Insider Trans	-4.85%	Shs Float	101.89M	Perf Month	-4.82%
Income	-181.10M	PEG	-	EPS next Q	-0.58	Inst Own	68.10%	Short Float / Ratio	6.22% / 6.95	Perf Quarter	-22.70%
Sales	256.20M	P/S	12.04	EPS this Y	-23.00%	Inst Trans	-1.73%	Short Interest	6.33M	Perf Half Y	15.03%
Book/sh	3.41	P/B	7.99	EPS next Y	-83.40%	ROA	-22.10%	Target Price	58.54	Perf Year	-16.13%
Cash/sh	3.93	P/C	6.94	EPS next 5Y	7.33%	ROE	-45.60%	52W Range	23.09 - 42.48	Perf YTD	-32.84%
Dividend	-	P/FCF	-	EPS past 5Y	-29.10%	ROI	-45.70%	52W High	-35.88%	Beta	1.00
Dividend %	-	Quick Ratio	6.70	Sales past 5Y	50.60%	Gross Margin	-	52W Low	17.97%	ATR	1.10
Employees	397	Current Ratio	6.70	Sales Q/Q	-51.20%	Oper. Margin	-70.50%	RSI (14)	38.94	Volatility	3.48% 3.91%
Optionable	Yes	Debt/Eq	0.72	EPS Q/Q	-41.20%	Profit Margin	-70.70%	Rel Volume	0.65	Prev Close	27.23
Shortable	Yes	LT Debt/Eq	0.72	Earnings	Aug 07 AMC	Payout	-	Avg Volume	910.74K	Price	27.24
Recom	2.10	SMA20	-3.97%	SMA50	-10.93%	SMA200	-16.32%	Volume	595,580	Change	0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform	$29
Mar-17-20	Initiated	Goldman	Neutral	$45

Show Previous Ratings

Sep-21-23 05:01AM	Insider Sell: CEO Christopher Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals Inc (GuruFocus.com)
Sep-11-23 07:30AM	Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023 (Business Wire)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-07-23 07:34PM	Is Arrowhead Pharmaceuticals (ARWR) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com)
Sep-01-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences (Business Wire)
08:32AM	Loading…
Aug-13-23 08:32AM	Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 99% over 5 years (Simply Wall St.)
Aug-10-23 08:10AM	ARWR: Enrollment Complete in PALISADE Phase 3 Trial of ARO-APOC3 in FCS... (Zacks Small Cap Research)
Aug-08-23 09:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript (Insider Monkey) -10.78%
09:13AM	Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-07-23 04:16PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (AP Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results (Business Wire)
Jul-24-23 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results (Business Wire)
Jul-17-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy (Business Wire)
Jul-06-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:52AM	Loading…
Jun-30-23 06:52AM	Daily Vickers Top Buyers & Sellers for 06/30/2023 (Argus Research)
Jun-27-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 (Business Wire)
Jun-24-23 08:15AM	Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease (Business Wire)
Jun-21-23 08:00PM	ARWR: What does Argus have to say about ARWR? (Argus Research)
Jun-14-23 06:34PM	Goldman Sachs Lifts S&P 500 Price Target; Here Are 2 High-Upside Stocks to Play the Bounce (TipRanks)
Jun-06-23 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences (Business Wire)
Jun-01-23 04:07PM	Arrowhead CEO Christopher Anzalone Addresses This 'Really Important Event' In Lung Disease (Investor's Business Daily)
07:30AM	Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics (Business Wire)
07:07AM	After a year of 4.1% returns, Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) share price drop last week may have less of an impact on institutional investors (Simply Wall St.)
May-23-23 07:30AM	Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH (Business Wire)
May-16-23 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome (Business Wire) -5.64%
May-15-23 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming Conferences (Business Wire)
May-11-23 09:27AM	ARWR: Interim Data for Phase 1/2 Trial of ARO-RAGE Shows Potential for Pulmonary TRiM Platform (Zacks Small Cap Research)
May-10-23 06:25AM	Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth? (Insider Monkey)
May-04-23 06:24AM	Arrowhead Pharmaceuticals Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
04:17PM	Loading…
May-02-23 04:17PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (AP Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results (Business Wire)
Apr-26-23 08:00PM	ARWR: Rating decreased to a SELL (Argus Research) +5.78%
07:06AM	Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates (Zacks)
Apr-25-23 01:19PM	Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars (Benzinga) +11.86%
11:20AM	Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday (Motley Fool)
07:30AM	Arrowhead Pharmaceuticals Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect (Business Wire)
Apr-18-23 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results (Business Wire)
Apr-17-23 08:17AM	Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up (Simply Wall St.)
Apr-16-23 05:21AM	Is Arrowhead Pharmaceuticals a Buy Now? (Motley Fool)
Apr-12-23 07:30AM	Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics (Business Wire) +8.88%
Apr-04-23 04:30PM	2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street (Motley Fool)
07:30AM	First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead (Business Wire)
Apr-03-23 07:30AM	Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK (Business Wire)
Mar-31-23 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Mar-20-23 07:30AM	Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 (Business Wire)
Mar-06-23 05:28AM	Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 329% gain (Simply Wall St.)
Mar-03-23 07:30AM	Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference (Business Wire)
Feb-28-23 07:30AM	Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases (Business Wire)
Feb-26-23 08:04AM	12 High Growth Healthcare Stocks to Buy (Insider Monkey)
Feb-15-23 11:29AM	JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals (Benzinga)
07:30AM	Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results (Business Wire)
Feb-08-23 02:13PM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript (Insider Monkey)
05:34AM	ARWR: Catalyst-Rich 2023 (Zacks Small Cap Research)
Feb-06-23 04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results (Business Wire) -8.79%
Feb-03-23 12:50PM	I Found a Good-Looking Arrowhead in This Biotech ETF (TheStreet.com)
Feb-02-23 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Jan-25-23 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results (Business Wire)
Jan-24-23 08:22AM	A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) (Simply Wall St.)
Jan-10-23 10:15AM	ARWR: Encouraging Results for Phase 2 SEQUOIA Trial (Zacks Small Cap Research) +9.08%
Jan-09-23 10:12AM	Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study (Benzinga) -18.99%
Dec-21-22 04:00PM	Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +12.63%
07:30AM	Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study (Business Wire)
Dec-20-22 07:30AM	Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen (Business Wire) +6.02%
Dec-15-22 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
11:19AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript (Insider Monkey)
Dec-08-22 08:00AM	Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout (Business Wire)
Nov-30-22 05:23AM	ARWR: Sells Olpasiran Royalty Interest for $250 Million (Zacks Small Cap Research) +7.37%
Nov-29-22 04:12PM	Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease (Investor's Business Daily) +7.11%
Nov-28-22 04:30PM	Edited Transcript of ARWR.OQ earnings conference call or presentation 28-Nov-22 9:30pm GMT (Thomson Reuters StreetEvents) -5.08%
04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results (Business Wire)
Nov-23-22 09:14AM	We Think Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Nov-21-22 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-14-22 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results (Business Wire)
Nov-09-22 08:49AM	Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones (GlobeNewswire) -8.53%
08:10AM	Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones (Business Wire)
Nov-07-22 04:08PM	Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline (Business Wire)
Oct-13-22 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-11-22 07:30AM	Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3 (Business Wire)
Oct-09-22 08:58AM	Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) recent 4.3% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Sep-07-22 06:46AM	Investing in Arrowhead Pharmaceuticals (NASDAQ:ARWR) five years ago would have delivered you a 982% gain (Simply Wall St.) +5.24%
Sep-01-22 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences (Business Wire)
Aug-17-22 07:30AM	Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis (Business Wire)
Aug-09-22 09:40AM	ARWR: Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates (Zacks Small Cap Research)
Aug-05-22 12:00AM	Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript (Motley Fool)
Aug-04-22 04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results (Business Wire)
Jul-20-22 04:00PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results (Business Wire)
Jul-08-22 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-05-22 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE (Business Wire) +8.90%
Jun-27-22 12:21PM	Drug reduces mutant protein that can lead to fibrosis in rare genetic liver disease (Reuters)
Jun-16-22 08:36AM	Arrowhead Pharmaceuticals (NASDAQ:ARWR) Is In A Strong Position To Grow Its Business (Simply Wall St.)
Jun-14-22 07:42AM	Baron Funds: We Retain Conviction in Arrowhead (ARWR) (Insider Monkey)
Jun-07-22 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences (Business Wire) +5.86%
May-26-22 07:30AM	Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics (Business Wire)
May-16-22 09:25AM	ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway (Zacks Small Cap Research)
May-10-22 04:00PM	Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results (Business Wire)
May-09-22 10:30AM	Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives (Business Wire) -11.38%
May-02-22 08:10AM	Could The Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
07:31AM	Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors (Business Wire)
07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences (Business Wire)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anzalone Christopher Richard	Chief Executive Officer	Sep 18	Option Exercise	4.75	57,755	274,336	3,819,093	Sep 20 06:10 PM
Anzalone Christopher Richard	Chief Executive Officer	Sep 18	Sale	28.12	57,755	1,624,223	3,761,338	Sep 20 06:10 PM
Oliver Tracie	Chief Commercial Officer	Jul 03	Sale	35.31	8,925	315,142	61,575	Jul 06 06:04 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jun 30	Sale	35.53	3,000	106,590	188,484	Jul 05 06:15 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jun 27	Sale	36.20	15,000	543,000	381,704	Jun 29 06:41 PM
GIVEN DOUGLAS B	Director	May 05	Sale	40.90	6,500	265,850	117,635	May 08 06:29 PM
Anzalone Christopher Richard	Chief Executive Officer	May 04	Option Exercise	2.01	50,000	100,500	3,811,338	May 05 07:04 PM
Anzalone Christopher Richard	Chief Executive Officer	May 04	Sale	39.52	50,000	1,975,792	3,761,338	May 05 07:04 PM
Anzalone Christopher Richard	Chief Executive Officer	May 03	Option Exercise	2.01	54,928	110,405	3,816,266	May 05 07:04 PM
Anzalone Christopher Richard	Chief Executive Officer	May 03	Sale	39.14	54,928	2,149,882	3,761,338	May 05 07:04 PM
OLUKOTUN ADEOYE Y	Director	Mar 03	Sale	32.65	11,350	370,578	7,867	Mar 06 06:04 PM
GIVEN DOUGLAS B	Director	Feb 27	Sale	32.62	875	28,542	13,000	Mar 01 06:14 PM
Waddill William D.	Director	Jan 09	Sale	30.00	3,200	96,000	28,950	Jan 11 08:23 PM
O'Brien Patrick	COO and General Counsel	Jan 05	Sale	37.39	15,000	560,850	413,375	Jan 06 07:30 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 05	Sale	37.40	13,803	516,232	191,484	Jan 06 07:24 PM
O'Brien Patrick	COO and General Counsel	Jan 03	Sale	38.33	17,500	670,802	363,375	Jan 05 07:10 PM
Hamilton James C	Chief Discovery/Trans Medicine	Jan 03	Sale	38.38	10,338	396,738	145,287	Jan 05 07:05 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Dec 29	Sale	40.00	30,625	1,225,000	336,704	Dec 30 05:12 PM
O'Brien Patrick	General Counsel	Dec 21	Option Exercise	6.15	32,000	196,800	380,875	Dec 22 08:01 PM
San Martin Javier	Chief Medical Officer	Nov 21	Sale	29.99	19,500	584,738	91,500	Nov 22 06:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARWR | Arrowhead Pharmaceuticals, Inc.

Upgrade your FINVIZ experience